Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Innovative Industrial Properties

Teladoc

These stocks could shine next year, assuming they don't stumble beforehand.

3 Wild-Card Stocks for the New Bull Market

Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Inovio Pharmaceuticals (INO) Stock?

Should Investors Buy Inovio for Its Coronavirus Vaccine?

Seres Therapeutics

Novavax

Pfizer

Twist Bioscience Corp

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2...

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18

Shares of Inovio Pharmaceuticals Inc. gained 0.6% in premarket trading on Monday after the company said it started dosing participants in a Phase 2 clinical trial for its experimental COVID-19 vaccine. Inovio plans to enroll 400 adults in the randomized, blinded, placebo-controlled study by the end of the year.

Inovio starts dosing participants in mid-stage COVID-19 vaccine trial

The company taps another partner to help make its coronavirus vaccine when, and if, it's approved.

Why Coronavirus Stock Inovio Pharmaceuticals Shot Higher Today

Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against SARS-CoV-2, issued an update on its vaccine program Thursday, sending the stock higher.  What Happened: The Plymouth, Pennsylvania-based company said it has executed an agreement with Kaneka Eurogentec, an affiliate of Japanese chemicals company Kaneka Corp., for manufacturing INO-4800 at Kaneka Eurogentec's GMP plasmid production scales.

Inovio Strikes Coronavirus Vaccine Manufacturing Deal With Kaneka Unit

While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders. The post Just Say No to Inovio Pharmaceuticals Stock appeared first on InvestorPlace.

Just Say No to Inovio Pharmaceuticals Stock

AbbVie

Regeneron Pharmaceuticals

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains

If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.

Count on the Advancement of DNA Medicine with Inovio Stock

Telesis Bio Inc

Vaxart

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.

4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

Abbott Labs

AstraZeneca

Gilead Sciences

Johnson & Johnson

Sorrento Therapeutics Inc

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.

Prepare for Phase 2 and a Comeback for Inovio

These dark horses are getting their second wind.

3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

Investors weren't impressed enough with the biotech's positive clinical data.

Why Inovio Stock Slid Today

The FDA has lifted a clinical hold on the biotech's phase 2 study, boosting its prospects for the future.

Is Inovio Back in the Coronavirus Vaccine Race?

Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?

Inovio Gets the Go-Ahead But It's Probably Too Late

PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's novel...

INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting

First commercial approvals could be for HPV therapies in 2022. Brain cancer (glioblastoma) data could indicate a multibillion-dollar opportunity.

Inovio: Accumulate For The HPV And Brain Cancer Therapies

INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.

Inovio Pharmaceutical's FDA Plight Makes It a Highly Risky Bet

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Monday the lifting of the FDA-imposed partial clinical hold on the start of the Phase 2 study of INO-4800, its DNA coronavirus vaccine candidate.  The Inovio Analyst: Roth Capital Partners analyst Jonathan Aschoff downgraded Inovio from Neutral to Sell and maintained an $8 price target.

Inovio Analyst: COVID-19 Competition Could Be Too Great

The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.

The Clock Is Ticking for Inovio Stock

One analyst thinks you should sell the biotech's shares.

Why Inovio Stock Plunged Today

Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.

Inovio Has Little to Show for Its Covid-19 Efforts

News for Inovio Pharmaceuticals Stock (INO)